An absurdly cheap healthcare stock to buy now
The pandemic has vastly accelerated the shift towards telehealth, making Cigna a long-term buy
![Online doctor's consultation © Getty Images](https://cdn.mos.cms.futurecdn.net/u9twqN2PL8XpzEEqjC8e2e-415-80.jpg)
A major problem during Covid-19 has been how to treat patients without having face-to-face meetings in surgeries. Enter telehealth: using technology and the internet to create online health centres.
Although not discussed as much as other pandemic boom sectors such as film streaming, food delivery or virtual offices, telehealth is potentially huge. Annual growth forecasts for the US range from 25% to 35% a year for the next five years, implying an industry worth $200bn-$400bn. McKinsey, a consultancy, estimates that $250bn of US healthcare spend could go virtual if conditions are right – an almost 100-fold leap from the $3bn of annual sales for US telehealth before the virus.
Health-services and insurance companies such as Cigna (NYSE: CI), UnitedHealthcare, Doctor on Demand and Hims & Hers have been responding by investing in the sector, raising money and reporting strong growth that supports the impressive outlook. Cigna’s current deal to buy privately-held telehealth business MDLive, in which it already held a stake, certainly looks astute. It gets one of the biggest US telehealth businesses, which is virtually looking after 60 million people round-the-clock every day and dispensing services ranging from urgent care to psychiatry. Buying the business not only brings Cigna millions more users, but also gives it a platform on which to integrate the purchase with its existing health offerings to provide more comprehensive services. These in turn should attract even more individuals and corporate employees.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
![https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748-320-80.jpg)
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Treating patients remotely is not entirely new. Telephone consultations, for example, have been around for years. But it’s always been a small part of medical interaction. Covid-19, as in other areas, has changed this. In the year before the pandemic, telehealth facilitated one in ten medical encounters in the US, according to a survey by researchers at McKinsey. Last year the number had soared to around half. And after a peak in April it has stabilised well above pre-Covid-19 levels.
After the virus
After Covid-19 the extreme circumstances that have had so many people working from home, ordering home deliveries and endlessly streaming television are unlikely to return. But none of these activities has gone away and they are likely to be more common than before the pandemic because habits have changed.
People want more, but not all, of their time working from home, for example; similarly, online shopping isn’t going into reverse but people will still want to visit exciting shops.
It’s the same with health. Patients will want (and need) to see GPs in person again, but others will prefer quick online consultations and immediate prescriptions. In a recent McKinsey survey of consumers, 40% said they’d keep using telehealth – only 11% were using it before Covid-19.
As for clinicians, 58% now take a more favourable view of it. The pandemic’s acceleration of telehealth adoption has given a glimpse of a more efficient healthcare model that answers some of the policy and funding challenges governments worldwide are struggling with.
Telehealth is here to stay and will become more appealing as technology keeps advancing. It’s not just about online surgeries and consultations, but also the proliferation of devices and gadgets to monitor and analyse patients from afar for immediate diagnoses, alerts and surgical interventions.
Health services are set to struggle with backlogs and growing user volumes for years. The enduring need to get costs down, increase medical access and treat patients faster should also underpin the growth of telehealth well beyond Covid-19.
Double digit earnings for half the price
There are two reasons for buying Cigna. First, it is valued at just ten times next year’s earnings – half the valuation of the overall market and far cheaper than leading peers in its sector.
This is despite double-digit earnings growth: in March the company told analysts that it could keep growing earnings by an annual 10%-13% a year over the long term, and next year profit growth would reach the top of that range.
The company also boosted its dividend, which could keep outpacing inflation. The share price does not, therefore, reflect the performance outlook of the core business.
The second reason to add this stock to your portfolio is that Cigna’s effort to build its business in telehealth increases exposure to a high-growth technology sector. The group’s acquisition of MDLive accelerates progress and provides integration and cross-selling opportunities.
At least some of the potential excitement about telehealth should feed through to Cigna’s financial returns and valuation but, again, this is not yet appreciated by the stockmarket.
So far this year the shares have lagged the S&P 500, America’s benchmark index.
However, almost all the two dozen or so analysts following Cigna are positive about its future and their consensus expectation is for the shares to rise by 25% from current levels to $295.
This healthcare conglomerate broadly covers three areas: health insurance for employers and government bodies; health services for individuals; and an overseas operation.
Cigna’s first quarter results in May beat expectations with quarterly sales of $41bn. Not only are the industry dynamics working in its favour while Wall Street is taking a positive view, the management’s own tone is upbeat and confident. This is a cheap, well-run business facing a bright future.
Stephen Connolly heads a family investment office, and has worked in investment banking and asset management for nearly 30 years (sc@plainmoney.co.uk)
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Stephen Connolly is the managing director of consultancy Plain Money. He has worked in investment banking and asset management for over 30 years and writes on business and finance topics.
-
Regulator moves to protect access to cash amid branch closures and disappearing ATMs
News The Financial Conduct Authority has told banks to start assessing if local communities have adequate cash access from mid-September
By Marc Shoffman Published
-
VAT hike on private school fees could come earlier than previously expected
The government could start charging VAT on private school fees as soon as January 2025, according to the latest reports. What does it mean for parents?
By Katie Williams Published
-
UK mid-caps: an improving outlook
UK mid-caps have perked up and the rally may run further, but long-term investors should remain selective
By Cris Sholto Heaton Published
-
The tobacco industry is going smoke-free - how to profit from it
Tobacco companies have realised their traditional products are on the wane. But new opportunities have opened up – and should prove lucrative
By Rupert Hargreaves Published
-
Is it time to invest in creative industries?
Any industrial strategy should not overlook the creative industries, one of our top national assets
By David C. Stevenson Published
-
Is Mercia Asset Management set for success?
Mercia Asset Management helps the government fund smaller companies in Britain’s regions. Should you invest?
By Rupert Hargreaves Published
-
British stocks set for a boost
British stocks are due for a bounce as the UK looks more stable compared to many economies
By Alex Rankine Published
-
Ocado shares jump by a fifth
Ocado takes a turn for the better after attractive profit forecasts were announced
By Dr Matthew Partridge Published
-
The AI boom is on borrowed time
The hype around the AI boom could be on its way out – but why?
By Alex Rankine Published
-
Diploma: a blue-chip set for strong growth
Diploma, whose niche products include seals and fasteners, serves an array of growth markets. Should you invest?
By Dr Mike Tubbs Published